EOFLOW

EOFlow Officially Launches iOS Version of the EOPatch App ‘Narsha’

▶ iOS version of the world’s first app for controlling wearable insulin pump ▶ Improved ease of use by replacing a portable controller with a smartphone app EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, today announces that it officially launches iOS Version of ‘Narsha,’ a smartphone application for wearable insulin pump in Korea. It has been nine months since the Company officially launched the Android application of Narsha. Narsha is the world’s first...

May. 17. 2022
EOFlow Announces Record Revenue for First Quarter 2022; Revenue of 949 Million KRW which is 137% of Last Year’s Annual Revenue

▶ Highest-ever quarterly revenue! Strong revenue growth from European sales; Menarini will progressively launch the product in Europe from 2Q22 onwards! ▶ EOFlow expects significant growth in revenue in 2022 from market launches in Europe, Indonesia, and the Middle East EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, announced its Q1 financial results ended on March 31, 2022. EOFlow announced its consolidated financial results: first quarter of 2022 revenue of 949 million Korean...

May. 16. 2022
EOFlow Has its First Clinical Study on EOPatch Published in Diabetes & Metabolism Journal

▶ A 4-Week, Two-Center, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of EOPatch in Well-Controlled Type 1 Diabetes Mellitus ▶ 4-week treatment with EOPatch was safe and led to clinically meaningful improvement in glycemic control compared to those with MDI or conventional insulin pump EOFlow Co. Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced today that its first clinical study results on the wearable insulin pump EOPatch in patients with type 1 diabetes were publ...

Apr. 11. 2022
EOFlow to Supply KRW48.8bn Worth of EOPatch to Gulf Drug of UAE

▶ A Major Export Deal for EOFlow’s Innovative Insulin Pump EOPatch EOFlow Co. Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced on March 31 that it has signed a contract with GulfDrug LLC (Gulf Drug) of the United Arab Emirates (UAE) to supply 48.8 billion Korean won (40 million US dollar) worth of EOPatch, a disposable and wearable insulin pump, over the course of five years. The Company said the contract amount is equivalent to 7043 percent (%) of its entire sales last year. T...

Apr. 04. 2022
EOPatch awarded GD (Good Design) designation

EOFLOW's wearable disposable insulin pump product, EOPatch, was recently awarded the highly selective Good Design (GD) designation. Hosted annually by Korea Institute of Design Promotion (KIDP) and sponsored by the Korean Ministry of Trade, Industry & Energy (MOTIE), the GD Selection is subject to highly competitive selection processes, and the designation is yet another validation of the excellence of the design and usability of EOPatch. The picture below is EOPatch on display during the Sele...

Dec. 13. 2017
Luis Malave joins as new president of EOFLOW

Mr. Luis Malave, a long-time industry insider who has contributed significantly to the emergence of the smart insulin patch pump industry, has joined EOFLOW as the new president. Luis was one of the earliest employees at Insulet and was the COO of the company at the time he left. He was also an early member of MiniMed. Prior to this, he also worked at Medtronic and University of Minnesota.

Oct. 17. 2017
Dr. David Klonoff joins as a Scientific Advisory Board member

EOFLOW announces that David Klonoff, M.D. has joined EOFLOW as the latest member of its Scientific Advisory Board. Dr. Klonoff is Medical Director of the Dorothy L. and James E. Frank Diabetes Research Institute of Mills-Peninsula Medical Center in San Mateo, California and a Clinical Professor of Medicine at UCSF. He has been a Principal Investigator on 110 clinical trials of diabetes drugs and devices, and has been lead investigator on multicenter trials for Novo, Sanofi, Diasome, and Medtronic. He was the lead investigator for th...

Oct. 16. 2017
Dr. Jonathan Woo joins EOFLOW as CSO

EOFLOW announces that Dr. Jonathan Woo has joined the company as the Chief Strategy Officer. Jonathan was the CEO and Co-Founder of Precursor Energetics, where he launched and managed a Silicon-valley venture-funded advanced material-design company in clean-tech area focusing on printable CIGS solar cell, thin-film Li-ion battery, and wearable/flexible thin-film-transistor display products using printed-electronics processes. He was the CTO and Co-Founder of Nanostellar, working in the area of nano-material design and development for auto...

Oct. 13. 2017
Luis Malave joins as a new board member of EOFLOW

EOFLOW announces that Luis Malave, a long time industry insider, has formally joined as a new board member as of October 1, 2017. Luis was one of the earliest employees at Insulet and was the COO of the company at the time he left. He was also an early member of MiniMed. Prior to this, he also worked at Medtronic and University of Minnesota.

Oct. 12. 2017
EOFLOW signs up HUONS as distribution partner for Korea

EOFLOW and Huons (www.huons.com) signed an agreement to appoint Huons an exclusive distributor in the Korean market for EOFLOW's disposable wearable insulin pump solution, EOPatch. Huons is one of the fastest growing pharmaceutical companies in Korea. "We are excited that EOPatch will allow many diabetic patients and their families better manage the disease and improve their quality of life," says Mr. Um, Key An, the president of Huons. You can read about more details from other news sites below (in Korean...

Sep. 07. 2017
EOFLOW sets up a US subsidiary

EOFLOW is announcing the establishment of EOFLOW, INC., a wholly owned subsidiary of EOFLOW Co., Ltd., in the heart of Silicon Valley, San Jose. The new subsidiary will be largely responsible for the global marketing operations of the whole EOFLOW. It is currently manned by some well-experienced and highly respected industry insiders whose names will be released later at opportune times.

Sep. 04. 2017
EOFLOW will be at the 2017 EASD, Lisbon (9/11-15)

EOFLOW will exhibit its commercial EOPatch wearable disposable insulin delivery product at the 2017 53rd EASD (European Association for the Study of Diabetes) held in Lisbon, Portugal, 9/11 - 9/15/2017. EOFLOW's booth is E.05. The company recently made its first submission for a regulatory approval of the patch pump product in Korea. Please contact us in advance if you'd like to arrange a meeting with our marketing team: info@eoflow.com

Aug. 21. 2017
EOPatch submitted for KFDS regulatory approval

EOFLOW recently applied for the regulatory approval of its first commercial product, EOPatch, with KFDS (Korean Food and Drug Safety). EOPatch is made up of a wearable disposable insulin pump patch ('Patch'), a smart-phone like controller ('ADM: Advanced Diabetes Manager'), and a management software that runs on a computer ('DDM: Diabetes Data Manager').

Aug. 21. 2017
EOFLOW featured in a magazine

EOFLOW was featured in a magazine published by SNUHB (Seoul National Hospital - Bundang). SNUH is widely considered one of the best hospitals in Korea, and EOFLOW is currently headquartered in Healthcare Innovation Park owned and managed by SNUH, which hosts scores of promising and outperforming biomedical companies large and small that the hospital sees strategic fit with.

Aug. 14. 2017

We use cookies. By continuing to use our site you accept our cookie policy. Find out more about our privacy policy here